U.S. FDA to review data on Vytorin cancer risk
WASHINGTON, Aug 21 (Reuters) - U.S. Food and Drug Administration officials plan to review recently publicized data that showed a higher rate of cancer in patients taking Merck & Co Inc (MRK.N: Quote, Profile, Research, Stock Buzz) and Schering-Plough Corp's (SGP.N: Quote, Profile, Research, Stock Buzz) cholesterol drug Vytorin.
The agency, in a notice posted on its website on Thursday, said it will take about three months before it receives final results from the so-called SEAS study. It will likely take another six months for the FDA to complete its review and draw any conclusions, it added. (Reporting by Susan Heavey; Editing by Tim Dobbyn)
© Thomson Reuters 2008 All rights reserved
Ads by Career Builder
Revenue Cycle Management/ Healthcare
Details: Growing Healthcare Consultancy organization...seeks experienced Healthcare Revenue Cycle Management...initiatives to healthcare providers and payers...
Work from Home as a Healthcare Recruiter
Details: ...from Home as a Healthcare Recruiter Health...an international healthcare recruiting and...represents high-demand healthcare professionals and...
Regional Operations Director - Healthcare
Details: ...Operations Director - Healthcare This position will...skills/experience: Healthcare Multi-Site Management...benefits including the healthcare industry's most...
Lawson Analyst - Payroll for healthcare
Details: ...experience within a healthcare industry environment...Application Analyst, Healthcare Systems, Payroll...Analyst - Payroll for healthcare position, and have...
Attacks fuel India-Pakistan tensions
